Developer docs
API playgroundTry for free, no card

Search company profiles

Ora Biomedical, Inc.

Full company profile

uuid0003h2w

Namestring
Ora Biomedical, Inc.
Legal namestring
Ora Biomedical, Inc.
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Ora Biomedical, Inc. is a Seattle-based longevity biotechnology company developing gerotherapeutics — small molecules and peptides that target the molecular biology of aging — using a proprietary high-throughput screening platform. The company's core technology, WormBot-AI, combines robotics, computer vision, and deep learning to automate lifespan and healthspan analysis in live Caenorhabditis elegans, claiming throughput approximately three orders of magnitude greater than conventional animal screening methods. Underpinning the platform is the Million Molecule Challenge (MMC), a crowdsourced initiative that aims to screen one million longevity interventions over five years while building an open-access database of per-worm survival data, Kaplan-Meier curves, and dose-response statistics.

The business model is hybrid. Direct-to-consumer sponsorships are sold through orabiomedical.com at $100 per single-compound intervention (with higher prices for combinations and custom experiments), targeting citizen scientists, biotech sponsors, and academic researchers. Larger dedicated research projects — such as the 601-compound mTOR modulator screen in collaboration with Rapamycin Longevity Labs — generate higher-value contract revenue. A fiscal-sponsor partnership with Lifespan.io enables tax-deductible donations and expands reach into the longevity advocacy community. Strategic positioning emphasizes the company's published claim that pilot screens have already identified mTOR modulators outperforming rapamycin, with a stated long-term objective of progressing hits through cell-culture and small-mammal validation toward FDA-approved therapeutics for age-related disease.

The founding team comprises Ben Blue (CEO), Brian Kennedy, Matt Kaeberlein (Board Chair), Mitchell Lee, and Jason Pitt (WormBot inventor), drawn primarily from the University of Washington longevity research ecosystem. Advisory bench includes commercial biotech operators Ryan Dittamore and Jesse Horwitz. Capitalization is thin: total disclosed equity raised is approximately $965K across a May 2022 round ($245K) and a January 2024 SEC Form D offering ($720K sold of $1,020,000), with the SEC filing indicating proceeds are intended to fund less than one year of operations. The company employs 1–10 people and is privately held.

Short descriptiontext

Ora Biomedical operates WormBot-AI, a high-throughput C. elegans screening platform combining robotics and deep learning to discover longevity therapeutics. It monetizes through crowdsourced Million Molecule Challenge sponsorships, custom research projects, and an open-access lifespan database serving citizen scientists, biotech sponsors, and academic researchers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
longevity drug discovery, high-throughput screening, C. elegans lifespan analysis, gerotherapeutics research, AI drug screening
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Longevity Drug Discovery & Screening Services
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Million Molecule Challenge Sponsorships
TypeOne Time License
Description

Individuals and organizations sponsor individual compound screenings at $100 per intervention. Sponsors can choose specific FDA-approved compounds, combinations, or use the random intervention machine. Data is co-owned by sponsor and Ora Biomedical, with option to deposit into open-access database.

orabiomedical.com
2Custom Combinatorial Experiments
TypeOne Time License
Description

Higher-cost custom experiments for 3+ intervention combinations, entire targeted libraries, or work outside the standard MMC scope. Pricing varies based on complexity and compound sourcing requirements.

orabiomedical.com
3Equity Financing (SEC Form D)
TypeTransaction Fee
Description

The company raised $720,000 of a $1,020,000 securities offering under SEC Rule 506(b), intended to fund operations for less than one year.

sec.gov
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details4 tiers
1Single compound intervention sponsorship
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$100 per intervention; sponsors choose from FDA-approved compound library or use random selection machine; includes triplicate testing, matched controls, and data delivery

orabiomedical.com
2Double compound combination screening
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Two-way combination experiments at increased cost; sponsors select specific combinations to test for synergistic effects on lifespan

orabiomedical.com
3Random intervention sponsorship
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$100; allows Ora to select any unsponsored intervention from the library, funding exploration of compound space

orabiomedical.com
4Custom combinatorial experiments (3+ interventions)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Higher cost due to complexity and compound sourcing; sponsors can request entire custom libraries, higher-order combinations, or work outside standard MMC scope

orabiomedical.com
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 2 records shown
1Million Molecule Challenge (MMC)
Description

Crowdsourced lifespan screening initiative where researchers, biotech sponsors, and citizen scientists can propose compounds to be tested on Ora's WormBot platform. The program aims to assess 1,000,000 longevity interventions in 5 years.

orabiomedical.com
+1 more record
Core offering1 text field

Ora Biomedical operates the WormBot-AI platform, a proprietary high-throughput drug screening system combining robotics, computer vision, and deep learning to automate lifespan, healthspan, behavioral, and mobility analysis in live Caenorhabditis elegans worms. The company monetizes this discovery engine primarily through the Million Molecule Challenge (MMC), a crowdsourced screening program where sponsors fund individual compound or combinatorial experiments at $100 per intervention, with results deposited into an open-access lifespan database. Ora Biomedical is also advancing preclinical longevity therapeutics (gerotherapeutics) targeting the molecular biology of aging.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Pilot mTOR screen identified at least one compound outperforming rapamycin in lifespan extension
+2 more records
Product overview1 text field

Ora Biomedical, Inc. is a longevity medicine company offering a unified platform combining the WormBot-AI discovery engine with the Million Molecule Challenge (MMC) crowdsourced screening service. The core offering consists of the WormBot-AI high-throughput robotics platform that combines robotics, computer vision, and deep learning for automated lifespan and healthspan analysis in C. elegans. The MMC enables sponsors to fund screening of specific or random compounds at $100 per intervention, with results deposited into the open-access MMC Database. The company also conducts proprietary research initiatives such as the mTOR Screening Project, all aimed at developing novel gerotherapeutics that target the molecular biology of aging to prevent and treat age-related disease.

Product and service5 records
1WormBot-AI Platform
CategoryDrug Discovery Platform
Description

High-throughput robotics platform combined with neural net AI that performs fully automated health and survival analysis in live Caenorhabditis elegans for drug discovery. Combines robotics, computer vision, and deep learning to run drug screening in live animals at a scale and speed unmatched by traditional methods, tracking hundreds of individual animals per trial with matched solvent-only controls.

2Million Molecule Challenge (MMC)
CategoryScreening Service
Description

Crowdsourced drug discovery initiative to assess 1,000,000 longevity interventions in 5 years using the WormBot-AI platform. Sponsors select single compounds, two-way combinations, or use a random intervention machine to fund screening experiments at $100 per intervention, with results co-owned by sponsor and Ora Biomedical and (by default) deposited into the open-access MMC Database.

3MMC Database
CategoryData Product
Description

Open-access community-screened Caenorhabditis elegans lifespan database containing ranked compounds with Kaplan-Meier survival curves, per-worm death events, dose information, sponsor details, and statistical analyses (p-values, effect sizes) from 770+ unique compounds, 56,000+ worm-level death events, and 96+ independent screening flights.

4Custom Combinatorial Experiments
CategoryScreening Service
Description

Higher-cost custom screening services for 3+ intervention combinations, full custom libraries, or experimental work outside the standard MMC scope, priced based on complexity and compound sourcing requirements. Available via the MMC Shop and intended for biotech sponsors and research institutions needing bespoke experimental designs.

5Longevity Therapeutics (Gerotherapeutics)
CategoryTherapeutics Pipeline
Description

Pipeline of novel small molecule gerotherapeutics discovered via the WormBot-AI platform and validated in cell culture and small mammal models, targeted at preventing and treating age-related disease through intervention in the molecular biology of aging.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2023-12-01
Description

Ora Biomedical partners with Lifespan.io as the fiscal sponsor of the Million Molecule Challenge. Lifespan.io is a nonprofit advocacy foundation advancing longevity science. This partnership allows MMC sponsorships to be made as tax-deductible donations through Lifespan.io's platform, expanding Ora's reach into the nonprofit charitable giving community. Lifespan.io directs funds toward MMC research and provides promotional support as a leading voice in the longevity advocacy space.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership to conduct the largest-ever lifespan analysis of 601 mTOR modulators. The joint project aims to identify compounds more potent than rapamycin in extending lifespan. Rapamycin Longevity Labs provides funding and scientific expertise, while Ora Biomedical contributes its WormBot-AI screening platform. This collaboration represents Ora's first major strategic partnership for targeted therapeutic discovery.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-founder Brian Kennedy serves as Distinguished Professor and Director of the Centre for Healthy Longevity at NUS. Co-founder Ben Blue featured on NUS Healthy Longevity lecture series. This academic partnership provides access to clinical trial design expertise and positions Ora for potential human or companion animal trials based on Dog Aging Project TRIAD insights.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Ora Biomedical references the Dog Aging Project TRIAD trial as a model for designing their own clinical trials. The company plans to pursue clinical trials in humans or companion animals based on worm-to-mammal validation pathways, drawing on insights from the Dog Aging Project's regulatory and endpoint design approach.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven small molecule drug discovery company using deep learning for hit identification. Directly comparable to Ora's AI/ML platform approach for novel therapeutic discovery, with similar partnership-driven business model.

TypeBroad incumbent
Description

Established computational chemistry and drug design platform serving pharma clients. Comparable to Ora's AI-driven discovery approach but operating at a much larger scale and across multiple therapeutic areas beyond aging.

TypeDirect peer
Description

AI-driven phenotypic drug discovery platform combining high-throughput biology with machine learning. Directly comparable to Ora's WormBot-AI model of automation + AI to scale phenotypic screening, though Recursion operates in cell-based assays rather than C. elegans.

TypeDirect peer
Description

AI/ML drug discovery company with an explicit focus on aging and longevity therapeutics. Closest competitor by combining generative AI with biological validation — overlaps Ora's mission of computationally discovering novel longevity interventions.

TypeDirect peer
Description

Machine learning-driven drug discovery company using high-throughput biology and predictive models. Comparable to Ora in fusing automation with AI to scale preclinical drug discovery, though focused on human cell-based disease models.

TypeDirect peer
Description

Clinical-stage longevity therapeutics company developing small molecules that target the molecular biology of aging. Comparable to Ora's gerotherapeutic ambition and overlapping on aging-biology targets, but at a far more advanced clinical stage.

TypeEmerging player
Description

Companion-animal longevity therapeutics company developing rapamycin-based interventions for dogs. Comparable to Ora via the rapamycin/mTOR axis and shared reference to the Dog Aging Project, though focused on canine rather than worm-to-human translation.

TypeEmerging player
Description

AI-driven longevity biotech using machine learning on human datasets to identify aging therapeutics. Comparable to Ora in combining AI with aging-biology focus, though Gero works from human data rather than C. elegans screens.

TypeBroad incumbent
Description

Well-capitalized longevity biotech ($3B+ raised) pursuing cellular reprogramming for age-related disease. Comparable to Ora in longevity therapeutic mission but operates with vastly greater resources and a different core technology platform.

TypeBroad incumbent
Description

Alphabet-backed longevity research company pursuing the biology of aging. Comparable to Ora as a longevity-focused R&D organization with deep resources, though Calico's research breadth and capital dwarf Ora's.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ora Biomedical, Inc.

Longevity Drug Discovery & Screening Servicesorabiomedical.com

Ora Biomedical operates WormBot-AI, a high-throughput C. elegans screening platform combining robotics and deep learning to discover longevity therapeutics. It monetizes through crowdsourced Million Molecule Challenge sponsorships, custom research projects, and an open-access lifespan database serving citizen scientists, biotech sponsors, and academic researchers.

What Ora Biomedical, Inc. does

Ora Biomedical, Inc. is a Seattle-based longevity biotechnology company developing gerotherapeutics — small molecules and peptides that target the molecular biology of aging — using a proprietary high-throughput screening platform. The company's core technology, WormBot-AI, combines robotics, computer vision, and deep learning to automate lifespan and healthspan analysis in live Caenorhabditis elegans, claiming throughput approximately three orders of magnitude greater than conventional animal screening methods. Underpinning the platform is the Million Molecule Challenge (MMC), a crowdsourced initiative that aims to screen one million longevity interventions over five years while building an open-access database of per-worm survival data, Kaplan-Meier curves, and dose-response statistics.

The business model is hybrid. Direct-to-consumer sponsorships are sold through orabiomedical.com at $100 per single-compound intervention (with higher prices for combinations and custom experiments), targeting citizen scientists, biotech sponsors, and academic researchers. Larger dedicated research projects — such as the 601-compound mTOR modulator screen in collaboration with Rapamycin Longevity Labs — generate higher-value contract revenue. A fiscal-sponsor partnership with Lifespan.io enables tax-deductible donations and expands reach into the longevity advocacy community. Strategic positioning emphasizes the company's published claim that pilot screens have already identified mTOR modulators outperforming rapamycin, with a stated long-term objective of progressing hits through cell-culture and small-mammal validation toward FDA-approved therapeutics for age-related disease.

The founding team comprises Ben Blue (CEO), Brian Kennedy, Matt Kaeberlein (Board Chair), Mitchell Lee, and Jason Pitt (WormBot inventor), drawn primarily from the University of Washington longevity research ecosystem. Advisory bench includes commercial biotech operators Ryan Dittamore and Jesse Horwitz. Capitalization is thin: total disclosed equity raised is approximately $965K across a May 2022 round ($245K) and a January 2024 SEC Form D offering ($720K sold of $1,020,000), with the SEC filing indicating proceeds are intended to fund less than one year of operations. The company employs 1–10 people and is privately held.

Ora Biomedical, Inc. firmographics

Firmographics
Name
Ora Biomedical, Inc.
Legal name
Ora Biomedical, Inc.
Website
https://orabiomedical.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Ora Biomedical operates WormBot-AI, a high-throughput C. elegans screening platform combining robotics and deep learning to discover longevity therapeutics. It monetizes through crowdsourced Million Molecule Challenge sponsorships, custom research projects, and an open-access lifespan database serving citizen scientists, biotech sponsors, and academic researchers.
Ownership category
akta.pro rank

Ora Biomedical, Inc. industry classification

Industry
Product category
Longevity Drug Discovery & Screening Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Longevity drug discovery
  • High-throughput screening
  • C. elegans lifespan analysis
  • Gerotherapeutics research
  • AI drug screening

Where Ora Biomedical, Inc. is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Ora Biomedical, Inc. business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Million Molecule Challenge Sponsorships: Individuals and organizations sponsor individual compound screenings at $100 per intervention. Sponsors can choose specific FDA-approved compounds, combinations, or use the random intervention machine. Data is co-owned by sponsor and Ora Biomedical, with option to deposit into open-access database.
  2. Custom Combinatorial Experiments: Higher-cost custom experiments for 3+ intervention combinations, entire targeted libraries, or work outside the standard MMC scope. Pricing varies based on complexity and compound sourcing requirements.
  3. Equity Financing (SEC Form D): The company raised $720,000 of a $1,020,000 securities offering under SEC Rule 506(b), intended to fund operations for less than one year.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goSingle compound intervention sponsorship
Unit PricingPay-as-you-goDouble compound combination screening
Unit PricingPay-as-you-goRandom intervention sponsorship
Unit PricingPay-as-you-goCustom combinatorial experiments (3+ interventions)

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Ora Biomedical, Inc. product offering

Product offering

Core offering

Ora Biomedical operates the WormBot-AI platform, a proprietary high-throughput drug screening system combining robotics, computer vision, and deep learning to automate lifespan, healthspan, behavioral, and mobility analysis in live Caenorhabditis elegans worms. The company monetizes this discovery engine primarily through the Million Molecule Challenge (MMC), a crowdsourced screening program where sponsors fund individual compound or combinatorial experiments at $100 per intervention, with results deposited into an open-access lifespan database. Ora Biomedical is also advancing preclinical longevity therapeutics (gerotherapeutics) targeting the molecular biology of aging.

Product overview

Ora Biomedical, Inc. is a longevity medicine company offering a unified platform combining the WormBot-AI discovery engine with the Million Molecule Challenge (MMC) crowdsourced screening service. The core offering consists of the WormBot-AI high-throughput robotics platform that combines robotics, computer vision, and deep learning for automated lifespan and healthspan analysis in C. elegans. The MMC enables sponsors to fund screening of specific or random compounds at $100 per intervention, with results deposited into the open-access MMC Database. The company also conducts proprietary research initiatives such as the mTOR Screening Project, all aimed at developing novel gerotherapeutics that target the molecular biology of aging to prevent and treat age-related disease.

Differentiator

Problem solved

Functional benefit

Brands

  • Million Molecule Challenge (MMC): Crowdsourced lifespan screening initiative where researchers, biotech sponsors, and citizen scientists can propose compounds to be tested on Ora's WormBot platform. The program aims to assess 1,000,000 longevity interventions in 5 years.
  • WormBot-AI

Products and services

  • WormBot-AI Platform High-throughput robotics platform combined with neural net AI that performs fully automated health and survival analysis in live Caenorhabditis elegans for drug discovery. Combines robotics, computer vision, and deep learning to run drug screening in live animals at a scale and speed unmatched by traditional methods, tracking hundreds of individual animals per trial with matched solvent-only controls.
  • Million Molecule Challenge (MMC) Crowdsourced drug discovery initiative to assess 1,000,000 longevity interventions in 5 years using the WormBot-AI platform. Sponsors select single compounds, two-way combinations, or use a random intervention machine to fund screening experiments at $100 per intervention, with results co-owned by sponsor and Ora Biomedical and (by default) deposited into the open-access MMC Database.
  • MMC Database Open-access community-screened Caenorhabditis elegans lifespan database containing ranked compounds with Kaplan-Meier survival curves, per-worm death events, dose information, sponsor details, and statistical analyses (p-values, effect sizes) from 770+ unique compounds, 56,000+ worm-level death events, and 96+ independent screening flights.
  • Custom Combinatorial Experiments Higher-cost custom screening services for 3+ intervention combinations, full custom libraries, or experimental work outside the standard MMC scope, priced based on complexity and compound sourcing requirements. Available via the MMC Shop and intended for biotech sponsors and research institutions needing bespoke experimental designs.
  • Longevity Therapeutics (Gerotherapeutics) Pipeline of novel small molecule gerotherapeutics discovered via the WormBot-AI platform and validated in cell culture and small mammal models, targeted at preventing and treating age-related disease through intervention in the molecular biology of aging.

Quantifiable outcome

  • Pilot mTOR screen identified at least one compound outperforming rapamycin in lifespan extension
  • +2 more outcomes

Companies that use Ora Biomedical, Inc.

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Ora Biomedical, Inc. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature4 records

Ora Biomedical, Inc. partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Lifespan.iocoreGTM or Marketing Partner · 1 December 2023Ora Biomedical partners with Lifespan.io as the fiscal sponsor of the Million Molecule Challenge. Lifespan.io is a nonprofit advocacy foundation advancing longevity science. This partnership allows MMC sponsorships to be made as tax-deductible donations through Lifespan.io's platform, expanding Ora's reach into the nonprofit charitable giving community. Lifespan.io directs funds toward MMC research and provides promotional support as a leading voice in the longevity advocacy space.
  • Rapamycin Longevity LabscoreStrategic or Co-development PartnerPartnership to conduct the largest-ever lifespan analysis of 601 mTOR modulators. The joint project aims to identify compounds more potent than rapamycin in extending lifespan. Rapamycin Longevity Labs provides funding and scientific expertise, while Ora Biomedical contributes its WormBot-AI screening platform. This collaboration represents Ora's first major strategic partnership for targeted therapeutic discovery.
  • National University of Singapore (NUS)coreStrategic or Co-development PartnerCo-founder Brian Kennedy serves as Distinguished Professor and Director of the Centre for Healthy Longevity at NUS. Co-founder Ben Blue featured on NUS Healthy Longevity lecture series. This academic partnership provides access to clinical trial design expertise and positions Ora for potential human or companion animal trials based on Dog Aging Project TRIAD insights.
  • Dog Aging ProjectminorStrategic or Co-development PartnerOra Biomedical references the Dog Aging Project TRIAD trial as a model for designing their own clinical trials. The company plans to pursue clinical trials in humans or companion animals based on worm-to-mammal validation pathways, drawing on insights from the Dog Aging Project's regulatory and endpoint design approach.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Ora Biomedical, Inc. competitors and assessment

Company assessment

Direct peers

  • Atomwise: AI-driven small molecule drug discovery company using deep learning for hit identification. Directly comparable to Ora's AI/ML platform approach for novel therapeutic discovery, with similar partnership-driven business model.
  • Recursion Pharmaceuticals: AI-driven phenotypic drug discovery platform combining high-throughput biology with machine learning. Directly comparable to Ora's WormBot-AI model of automation + AI to scale phenotypic screening, though Recursion operates in cell-based assays rather than C. elegans.
  • Insilico Medicine: AI/ML drug discovery company with an explicit focus on aging and longevity therapeutics. Closest competitor by combining generative AI with biological validation — overlaps Ora's mission of computationally discovering novel longevity interventions.
  • Insitro: Machine learning-driven drug discovery company using high-throughput biology and predictive models. Comparable to Ora in fusing automation with AI to scale preclinical drug discovery, though focused on human cell-based disease models.
  • BioAge Labs: Clinical-stage longevity therapeutics company developing small molecules that target the molecular biology of aging. Comparable to Ora's gerotherapeutic ambition and overlapping on aging-biology targets, but at a far more advanced clinical stage.

Broad incumbents

  • Schrödinger, Inc. Established computational chemistry and drug design platform serving pharma clients. Comparable to Ora's AI-driven discovery approach but operating at a much larger scale and across multiple therapeutic areas beyond aging.
  • Altos Labs: Well-capitalized longevity biotech ($3B+ raised) pursuing cellular reprogramming for age-related disease. Comparable to Ora in longevity therapeutic mission but operates with vastly greater resources and a different core technology platform.
  • Calico Life Sciences: Alphabet-backed longevity research company pursuing the biology of aging. Comparable to Ora as a longevity-focused R&D organization with deep resources, though Calico's research breadth and capital dwarf Ora's.

Emerging players

  • Loyal for Dogs: Companion-animal longevity therapeutics company developing rapamycin-based interventions for dogs. Comparable to Ora via the rapamycin/mTOR axis and shared reference to the Dog Aging Project, though focused on canine rather than worm-to-human translation.
  • Gero: AI-driven longevity biotech using machine learning on human datasets to identify aging therapeutics. Comparable to Ora in combining AI with aging-biology focus, though Gero works from human data rather than C. elegans screens.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Ora Biomedical, Inc. social profiles

Digital presence

Ora Biomedical, Inc. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ora Biomedical, Inc. leadership team

Management profile

Number of profiles

Profiles7 records

Ora Biomedical, Inc. funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ora Biomedical, Inc. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ora Biomedical, Inc.

What does Ora Biomedical, Inc. do?

Ora Biomedical operates the WormBot-AI platform, a proprietary high-throughput drug screening system combining robotics, computer vision, and deep learning to automate lifespan, healthspan, behavioral, and mobility analysis in live Caenorhabditis elegans worms. The company monetizes this discovery engine primarily through the Million Molecule Challenge (MMC), a crowdsourced screening program where sponsors fund individual compound or combinatorial experiments at $100 per intervention, with results deposited into an open-access lifespan database. Ora Biomedical is also advancing preclinical longevity therapeutics (gerotherapeutics) targeting the molecular biology of aging.

Is Ora Biomedical, Inc. a public or private company?

Ora Biomedical, Inc. is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Ora Biomedical, Inc. founded?

Ora Biomedical, Inc. was founded in 2021. It employs 11 to 50 people.

Where is Ora Biomedical, Inc. based?

Ora Biomedical, Inc. is headquartered in Seattle, United States, in the North America region.

How does Ora Biomedical, Inc. make money?

Three revenue lines are on record. Million Molecule Challenge Sponsorships are the primary driver. The others are custom Combinatorial Experiments and equity Financing (SEC Form D).

Who are Ora Biomedical, Inc.'s main competitors?

Direct peers on record are Atomwise, Recursion Pharmaceuticals, Insilico Medicine, Insitro and BioAge Labs. Broad incumbents are Schrödinger, Inc., Altos Labs and Calico Life Sciences. Emerging players are Loyal for Dogs and Gero.

Does Ora Biomedical, Inc. have an API?

No public API is recorded for Ora Biomedical, Inc..

What industry is Ora Biomedical, Inc. in?

Ora Biomedical, Inc.'s product category is Longevity Drug Discovery & Screening Services. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals